📰 Multidisciplinary Head News
Multidisciplinary Head News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multidisciplinary Head. Real-time updates on events, politics, business and more.
May 11, 2022
Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial...
April 28, 2022
28.04.2022 - Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV (enfortumab vedotin-ejfv), TUKYSA (tucatinib), ADCETRIS (brentuximab vedotin) and TIVDAK (tisotumab ...
March 1, 2022
High response rate with oncolytic virus plus immunotherapy in cutaneous lesions
February 28, 2022
High precision for T stage, extracapsular extension, BRAF mutation
February 27, 2022
High precision for T stage, extracapsular extension, BRAF mutation
February 25, 2022
A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.In addition, findings from the retrospective clinical case series suggested the biomarker test may detect disease recurrence earlier than imaging or other surveillance methods, allowing
January 8, 2021
Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study eval...